L
LLAI
vs
F
FTSE All Share Index
Over the past 12 months, LLAI has underperformed FTSE All Share Index, delivering a return of 0% compared to FTSE All Share Index's 0% growth.
Stocks Performance
LLAI vs FTSE All Share Index
Performance Gap
LLAI vs FTSE All Share Index
Performance By Year
LLAI vs FTSE All Share Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
LungLife AI Inc
Glance View
Lunglife AI, Inc. engages in the development of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence enabled molecular analysis of cancer biomakers in blood. The company is headquartered in Thousand Oaks, California and currently employs 13 full-time employees. The company went IPO on 2021-07-08. The firm is focused on cancer treatment and management through the artificial intelligence (AI) enabled molecular analysis of cancer biomarkers in blood. The company is focused on lung cancer from simple blood draw diagnostic solutions. Its technologies include LiquidBiopsy. LiquidBiopsy uses a blood draw, rather than a tissue biopsy, to discover the genomic mutations present or absent within an individual that may be associated with lung cancer. The firm's LungLB test is positioned to bring certainty into early stage diagnosis confirming for clinicians whether to refer onto biopsy where the low-dose computed tomography (LDCT) scan reveals suspicious nodules.
